ASCO GI: Drug Active in Resistant GIST

SAN FRANCISCO (MedPage Today) — Two-thirds of patients with advanced gastrointestinal stromal tumors (GIST) achieved disease control after second- and third-line treatment with sorafenib (Nexavar), results of a small clinical trial showed.

Post a Comment

Comments are closed.